Abstract
Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.
Keywords: noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft
Letters in Drug Design & Discovery
Title: Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene
Volume: 1 Issue: 1
Author(s): M. Boyd, S. Ross, J. Owens, D. Hunter, J. Babich, M. R. Zalutsky, T. G. Hamilton, S. Bell and R. J. Mairs
Affiliation:
Keywords: noradrenaline transporter, mibg, gene therapy, targeted radiotherapy, xenograft
Abstract: Meta-[131I]iodobenzylguanidine ([131I]MIBG), used for neuroblastoma treatment, binds to the noradrenaline transporter (NAT). After NAT gene transfection, other tumour types might be treatable with [131I]MIBG. At 14 MBq, carrier-added [131I]MIBG (1110 MBq / mg) delayed tumour regrowth in NAT gene-transfected xenografts by 39-days, while no-carrier-added [131I]MIBG ( > 104 GBq / mg) cured 100% of tumours.
Export Options
About this article
Cite this article as:
Boyd M., Ross S., Owens J., Hunter D., Babich J., Zalutsky R. M., Hamilton G. T., Bell S. and Mairs J. R., Preclinical Evaluation of no-Carrier-Added [131I]Meta-Iodobenzyl Guanidine, for the Treatment of Tumours Transfected with the Noradrenaline Transporter Gene, Letters in Drug Design & Discovery 2004; 1 (1) . https://dx.doi.org/10.2174/1570180043485743
DOI https://dx.doi.org/10.2174/1570180043485743 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells
CNS & Neurological Disorders - Drug Targets Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Novel Chemotherapeutic Agents - The Contribution of Scorpionates
Current Medicinal Chemistry Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry CD248: Reviewing its Role in Health and Disease
Current Drug Targets General Anesthetics in Pediatric Anesthesia: Influences on the Developing Brain
Current Drug Targets Pluripotent Stem Cell-Derived Somatic Stem Cells as Tool to Study the Role of MicroRNAs in Early Human Neural Development
Current Molecular Medicine A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Quadruplex DNA: A Promising Drug Target for the Medicinal Inorganic Chemist
Current Topics in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy